Rubicon Research Limited (NSE:RUBICON)

India flag India · Delayed Price · Currency is INR
967.90
-9.85 (-1.01%)
At close: May 27, 2026
Market Cap161.08B
Revenue (ttm)15.98B +87.2%
Net Income2.06B +126.6%
EPS13.03 +120.6%
Shares Out 164.75M
PE Ratio75.01
Forward PE53.07
Dividendn/a
Ex-Dividend Daten/a
Volume78,555
Open988.00
Previous Close977.75
Day's Range957.10 - 988.00
52-Week Range570.75 - 1,015.70
Betan/a
AnalystsStrong Buy
Price Target910.00 (-5.98%)
Earnings DateMay 29, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ... [Read more]

Industry Pharmaceutical Preparations
Founded 1999
Employees 903
Stock Exchange National Stock Exchange of India
Ticker Symbol RUBICON
Full Company Profile

Financial Performance

In fiscal year 2025, Rubicon Research's revenue was 12.84 billion, an increase of 50.40% compared to the previous year's 8.54 billion. Earnings were 1.34 billion, an increase of 47.63%.

Financial Statements